You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
生物股顯著揚 金斯瑞漲11%創三年高 復銳醫療急漲19%創上市高
阿思達克 05-31 15:50
生物股今天顯著上揚,尤其是附屬治療多發性骨髓瘤藥物總緩解率升至98%的金斯瑞生物科技(01548.HK)高見30.8元,創三年高,現造30.3元,急漲11%,成交增至2,320萬股。和鉑醫藥-B(02142.HK)也升破去年12月首掛日所造上市高位11.94元,最高見12.16元(暫仍受制上市價12.38元),現造11.84元,續升12%,成交急增至2,108萬股。康希諾生物-B(06185.HK)升8.2%報342.2元,股價重越10天及20天線。

藍籌藥明生物(02269.HK)、諾誠健華-B(09969.HK)及康方生物-B(09926.HK)升約5%-7.5%,分別高見120.9元、24.7元及66.5元。此外,上周獲野村升價至13.7元的藍籌石藥(01093.HK)回升3.91%曾高見12.34元創近三年高。由復星醫藥(02196.HK)分拆上市的以色列醫學美容器械製造商復銳醫療科技(01696.HK)升破上周所創上市高位19.32元,最高見21.55元,現造21.05元,回升19%,成交增至740萬股。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account